Evidence map›Paper›PMID 28533357›Full record

ArticleJournal of leukocyte biology2017

TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs.

Haejung Won, Dayson Moreira, Chan Gao, Priyanka Duttagupta, Xingli Zhao, Edwin Manuel, Don Diamond, Yate-Ching Yuan, Zheng Liu, Jeremy Jones and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of leukocyte biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Human Group IIA Secreted Phospholipase AInternational journal of molecular sciences · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. TLR9: A Double-Dealing Toll-Like Receptor.ImmunoTargets and therapy · 2025
    Review
  8. Review
  9. Article
  10. Review
  11. Activation of STING in Response to Partial-Tumor Radiation Exposure.International journal of radiation oncology, biology, physics · 2023
    Article
  12. Review
  13. Article
  14. Leukemia inhibitory factor, a double-edged sword with therapeutic implications in human diseases.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Haejung WonDepartment of Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Dayson MoreiraDepartment of Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Chan GaoDepartment of Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Priyanka DuttaguptaDepartment of Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Xingli ZhaoDepartment of Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Edwin ManuelDepartment of Experimental Therapeutics, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Don DiamondDepartment of Experimental Therapeutics, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Yate-Ching YuanDepartment of Molecular Medicine, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Zheng LiuDepartment of Molecular Medicine, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Jeremy JonesDepartment of Cell Biology, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Massimo D'ApuzzoDepartment of Pathology, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA; and.
Sumanta PalDepartment of Medical Oncology, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Marcin KortylewskiDepartment of Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA; mkortylewski@coh.org.
City Of Hope National Medical Center · US

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3M
Transplant for Lymphoma:Therapy-Related LeukemiaP50CA107399 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI FORMAN, STEPHEN J, KWAK, LARRY W · 2004 to 2022
$35.5M
NCI NIH HHS P30 CA033572NCI NIH HHS P50 CA107399
6 · The paper itself

Abstract

Proinflammatory signals promote prostate tumorigenesis and progression, but their origins and downstream effects remain unclear. We recently demonstrated that the expression of an innate immune receptor, TLR9, by prostate cancer cells is critical for their tumor-propagating potential. We investigated whether cancer cell-intrinsic TLR9 signaling alters composition of the prostate tumor microenvironment. We generated Ras/Myc (RM9) and Myc-driven (Myc-CaP) prostate cancer cells expressing the tetracycline-inducible gene

Indexed as

AnimalsCell Line, TumorChromatin ImmunoprecipitationFlow CytometryGene Expression ProfilingHeterograftsHigh-Throughput Nucleotide SequencingHumansLeukemia Inhibitory FactorMaleMiceMice, Inbred C57BLMyeloid-Derived Suppressor CellsNeutrophilsProstatic NeoplasmsReal-Time Polymerase Chain ReactionLeukemia Inhibitory FactorLIF protein, humanToll-Like Receptor 9CpGimmunosuppressionoligonucleotide therapeuticsSTAT3tumor microenvironment

Identifiers

PMID28533357
PMCPMC5505743
OpenAlexW2617763968

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.